These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19754407)

  • 1. Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson's disease.
    Lindsley CW; Niswender CM; Engers DW; Hopkins CR
    Curr Top Med Chem; 2009; 9(10):949-63. PubMed ID: 19754407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.
    Niswender CM; Johnson KA; Weaver CD; Jones CK; Xiang Z; Luo Q; Rodriguez AL; Marlo JE; de Paulis T; Thompson AD; Days EL; Nalywajko T; Austin CA; Williams MB; Ayala JE; Williams R; Lindsley CW; Conn PJ
    Mol Pharmacol; 2008 Nov; 74(5):1345-58. PubMed ID: 18664603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mGluR4 positive allosteric modulators with potential for the treatment of Parkinson's disease: WO09010455.
    East SP; Gerlach K
    Expert Opin Ther Pat; 2010 Mar; 20(3):441-5. PubMed ID: 20180624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
    Célanire S; Campo B
    Expert Opin Drug Discov; 2012 Mar; 7(3):261-80. PubMed ID: 22468956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease.
    Le Poul E; Boléa C; Girard F; Poli S; Charvin D; Campo B; Bortoli J; Bessif A; Luo B; Koser AJ; Hodge LM; Smith KM; DiLella AG; Liverton N; Hess F; Browne SE; Reynolds IJ
    J Pharmacol Exp Ther; 2012 Oct; 343(1):167-77. PubMed ID: 22787118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mGlu
    Charvin D
    Neuropharmacology; 2018 Jun; 135():308-315. PubMed ID: 29578036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature.
    Lindsley CW; Hopkins CR
    Expert Opin Ther Pat; 2012 May; 22(5):461-81. PubMed ID: 22506633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson's disease: translational gaps or a failing industry innovation model?
    Doller D; Bespalov A; Miller R; Pietraszek M; Kalinichev M
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1323-1338. PubMed ID: 33074728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.
    Hopkins CR; Lindsley CW; Niswender CM
    Future Med Chem; 2009 Jun; 1(3):501-13. PubMed ID: 20161443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.
    Litim N; Morissette M; Di Paolo T
    Neuropharmacology; 2017 Mar; 115():166-179. PubMed ID: 27055772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
    Niswender CM; Jones CK; Lin X; Bubser M; Thompson Gray A; Blobaum AL; Engers DW; Rodriguez AL; Loch MT; Daniels JS; Lindsley CW; Hopkins CR; Javitch JA; Conn PJ
    ACS Chem Neurosci; 2016 Sep; 7(9):1201-11. PubMed ID: 27441572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Putative mGluR4 positive allosteric modulators activate G
    Abulwerdi G; Stoica BA; Loane DJ; Faden AI
    Neurochem Int; 2020 Sep; 138():104770. PubMed ID: 32454165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orthosteric versus allosteric GPCR activation: the great challenge of group-III mGluRs.
    Flor PJ; Acher FC
    Biochem Pharmacol; 2012 Aug; 84(4):414-24. PubMed ID: 22554564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment.
    Marino MJ; Williams DL; O'Brien JA; Valenti O; McDonald TP; Clements MK; Wang R; DiLella AG; Hess JF; Kinney GG; Conn PJ
    Proc Natl Acad Sci U S A; 2003 Nov; 100(23):13668-73. PubMed ID: 14593202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors.
    Marino MJ; Conn PJ
    Curr Opin Pharmacol; 2006 Feb; 6(1):98-102. PubMed ID: 16368268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4).
    Williams R; Johnson KA; Gentry PR; Niswender CM; Weaver CD; Conn PJ; Lindsley CW; Hopkins CR
    Bioorg Med Chem Lett; 2009 Sep; 19(17):4967-70. PubMed ID: 19640716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease.
    Amalric M; Lopez S; Goudet C; Fisone G; Battaglia G; Nicoletti F; Pin JP; Acher FC
    Neuropharmacology; 2013 Mar; 66():53-64. PubMed ID: 22664304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the metabotropic glutamate receptor mGluR4 for the treatment of diseases of the central nervous system.
    Marino MJ; Hess JF; Liverton N
    Curr Top Med Chem; 2005; 5(9):885-95. PubMed ID: 16178733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reprint of Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.
    Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S
    Neuropharmacology; 2017 Mar; 115():115-127. PubMed ID: 28216000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery, Structure-Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4.
    Charvin D; Pomel V; Ortiz M; Frauli M; Scheffler S; Steinberg E; Baron L; Deshons L; Rudigier R; Thiarc D; Morice C; Manteau B; Mayer S; Graham D; Giethlen B; Brugger N; Hédou G; Conquet F; Schann S
    J Med Chem; 2017 Oct; 60(20):8515-8537. PubMed ID: 28902994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.